Brett Staahl PhD

Brett T. Staahl is the co-founder and VP of External Innovation at Scribe Therapeutics. Previously, he was a Postdoctoral Fellow in the lab of Jennifer Doudna, where he pioneered the use of CRISPR ribonucleoproteins, developed robust methods to deliver the proteins to various cell types both in vivo and ex vivo, and demonstrated that they could be used safely and effectively to inactivate disease-causing genes and slow neurodegeneration. He has also worked at and consulted for other biotech startups. Brett has over 20 scientific publications in top-tier journals, several patents issued and pending, and has received numerous research grants and awards, including the F. Hoffmann-La Roche Postdoctoral Fellowship.

Before completing his postdoctoral work at the University of California, Berkeley, Brett received his B.S. in Molecular, Cellular, and Developmental Biology from the University of Colorado, Boulder, and his Ph.D. in Developmental Biology from Stanford University, where he studied the genetic circuitry underlying development of the mammalian nervous system and discovered de novo function-altering mutations in the genes of sporadic Amyotrophic Lateral Sclerosis (ALS) patients.